Pridopidine in Huntington's Disease (PROOF-HD)
Phase 3 CompletedManifest Huntington's Disease
Target intervention
Pridopidine 45mg BID (sigma-1 receptor agonist)
Primary endpoint
cUHDRS at 65 weeks
Summary
Failed primary on cUHDRS; subgroup analyses suggested benefit in patients not on anti-dopaminergic background therapy.
Protocol timeline
Phase I
Phase II
Phase III
Phase IV
Current status Completed
Enrolled n = 499